Emtricitabine Cyclic-II impurity

Emtricitabine Cyclic-II impurity is a structurally related synthetic byproduct arising from the cyclization of 1,3-dioxolane moieties during Emtricitabine synthesis. It features a 1,3-dioxolan-4-one core fused to a substituted cyanoethylamine chain, with a key hydroxyl group at C-5 and an exocyclic amino functionality. This impurity diverges from the parent drug through a five-membered cyclic ether ring instead of the native 1,3-dioxolane ring, resulting in altered hydrogen bonding and steric hindrance. It serves as a critical HPLC reference standard for quantifying process-related impurities in Emtricitabine active pharmaceutical ingredients.